Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 82 clinical trials
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

This phase IIB trial studies how well enzalutamide and paclitaxel before surgery works in treating patients with stage I-III androgen receptor-positive triple-negative breast cancer. Androgens can cause the growth of triple-negative breast cancer. Anti-hormone therapy, such as enzalutamide, prevent androgen from binding to the androgen receptor, thereby decreasing cell growth …

erbb2
triple-negative breast cancer
epidermal growth factor receptor
axillary lymph node dissection
progesterone receptor
  • 0 views
  • 21 Mar, 2021
  • 2 locations
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

subtype is present in approximately 6.6-11.0% of HR+/HER2-negative tumors and might express either HER2, estrogen receptor (ER) or progesterone receptor (PR), we also know that HER2-E is present twice as

erbb2
gonadotropin releasing hormone
progesterone receptor
estrogen
estradiol
  • 0 views
  • 26 Jan, 2021
  • 15 locations
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

This phase I trial studies how well chemokine modulation therapy and standard chemotherapy given before surgery work in treating patients with early stage triple negative breast cancer. Chemokine modulation therapy, including celecoxib, recombinant interferon alfa-2b, and rintatolimod, may stimulate the immune system and stop tumor cells from growing. Drugs used …

doxorubicin
ejection fraction
chemokine modulation therapy
cancer
recombinant interferon alfa-2b
  • 1 views
  • 26 Jan, 2021
  • 1 location
A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer

This trial studies how well a text-based intervention works in improving adherence to hormone therapy in patients with stage I-III hormone receptor positive breast cancer. Women often require long term therapy with adjuvant hormone therapy to prevent the cancer from returning and to improve overall survival. Side effects from hormone …

cancer
hormone therapy
endocrine therapy
  • 0 views
  • 05 Apr, 2021
  • 7 locations
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

This phase I trial studies the side effects and best dose of genetically modified T-cell therapy in treating patients with receptor tyrosine kinase-like orphan receptor 1 positive (ROR1+) chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), stage IV non-small cell lung cancer (NSCLC), or triple negative …

crizotinib
remission
progesterone receptor
tositumomab
purine analog
  • 87 views
  • 20 Jul, 2021
  • 1 location
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

This phase II trial studies how well atorvastatin works in treating patients with stages IIb-III triple negative breast cancer who did not achieve a pathologic complete response to neoadjuvant chemotherapy. Pathologic complete response is the lack of all signs of cancer in tissue samples removed during surgery after upfront chemotherapy. …

erbb2
triple-negative breast cancer
inflammatory breast cancer
eosin
epidermal growth factor receptor
  • 0 views
  • 25 Jan, 2021
  • 1 location
Abemaciclib in Treating Patients With Surgically Resectable Chemotherapy Resistant Triple Negative Breast Cancer

This phase II trial studies how well abemaciclib works in treating patients with triple negative breast cancer that can be removed by surgery (resectable) and does not respond to treatment with chemotherapy. Abemaciclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

erbb2
progesterone receptor
5-fluorouracil
epirubicin
invasive breast cancer
  • 6 views
  • 19 Jun, 2021
  • 6 locations
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

This phase I trial studies the side effects and best dose of PI3Kbeta inhibitor AZD8186 when given together with docetaxel in treating patients with solid tumors with PTEN or PIK3CB mutations that have spread to other places in the body (metastatic) or cannot be removed by surgery. PI3Kbeta inhibitor AZD8186 …

solid tumors
docetaxel
androgen therapy
MRI
estrogen
  • 61 views
  • 09 Jul, 2021
  • 2 locations
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate …

erbb2
pd-l1
infarction
positron emission tomography
trastuzumab
  • 0 views
  • 26 Jun, 2021
  • 11 locations
A Study of XmAb 23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors.

erbb2
nasopharyngeal carcinoma
squamous cell carcinoma of head and neck
breast carcinoma
treatment regimen
  • 133 views
  • 25 May, 2021
  • 15 locations